35Pharma Secures $53 Million in Series C Funding for Revolutionary Cardiometabolic Disease Therapeutics

In a significant stride toward advancing its innovative pipeline, 35Pharma, a clinical-stage biopharmaceutical company based in Montreal, has successfully raised $53 million in a recent funding round. Specializing in TGF-beta superfamily therapeutics, 35Pharma is at the forefront of developing groundbreaking treatments for cardiometabolic diseases and obesity—conditions that affect millions of individuals worldwide. This new capital will enable the company to accelerate its research and development efforts, particularly in advancing clinical trials for its proprietary compounds designed to neutralize harmful TGF-beta ligands while preserving essential homeostatic functions. As a leader in TGF-beta biology, 35Pharma’s unique approach harnesses superior protein engineering to create therapies that hold the promise of dramatically improving patients' quality of life. The commitment of the team at 35Pharma reflects a deep-seated sense of urgency to translate rigorous scientific discovery into effective, life-changing treatments. Located in the vibrant biotech hub of Montreal, our R&D and office facilities foster collaboration among a talented and diverse team of professionals dedicated to the mission of serving patients in need. With this new funding, 35Pharma is poised to make significant strides that could reshape the landscape of cardiometabolic care. For those inspired by our culture of innovation and commitment to patient welfare, we encourage you to explore career opportunities with us: https://35pharma.com/careers/.